

Identity:

Title: Professor
 Family Name(s): Tocchetti
 First Name(s): Carlo Gabriele
 Age: 50

Photo:**Application for the following position in the HFA Board or Nominating Committee:**

Ordinary Board member

Place of work

If you work in multiple places, please provide the one where you spend the most time or that you consider to be your main place of practice.

Institute/organisation:	Federico II University
Department:	Department of Translational Medical Sciences
Address:	via Pansini 5, Napoli
Post code / Zip:	80131
Country:	Italy

General Curriculum Vitae (500 words max)

Please also include your H index and top 5 to 10 publications in the last 5 years

Current position:

Associate Professor of Medicine
 Director, Internal Medicine Unit for cancer patients

Recent research supports:

2022: **€ 763.659 grant** from the Italian Ministry of Health for the 2-year project PNRR-MAD-2022-12376632 - New molecular targets for the prevention of anthracycline-induced cardiotoxicity: a translational study. Prof Tocchetti is PI of Unit 4 (Unit 1 Prof Sebastiano Sciarretta, IRCCS Neuromed; Unit 2 Dr Cristina Banfi, IRCCS Centro Cardiologico Monzino; Unit 3 Prof Pietro Ameri IRCCS Ospedale Policlinico San Martino)

h-index 58

1. Salloum FN, **Tocchetti CG (co-first author)**, et al; International Cardio-Oncology Society. Priorities in Cardio-Oncology Basic and Translational Science: GCOS 2023 Symposium Proceedings: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2023 Sep 27;5(6):715-731. doi: 10.1016/j.jacc.2023.08.003. eCollection 2023 Dec. PMID: 38205010
2. Ciccarelli M, ..., **Tocchetti CG**. Acute heart failure: mechanisms and pre-clinical models-a Scientific Statement of the ESC Working Group on Myocardial Function. Cardiovasc Res. 2023 Nov 15;119(14):2390-2404. doi: 10.1093/cvr/cvad088. PMID: 37967390

Paper highlighted by the cover image

3. Lyon AR, López-Fernández T, ..., **Tocchetti CG**, van der Meer P, van der Pal HJH; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244. PMID: 36017568

4. Cuomo A, Mercurio V, ..., **Tocchetti CG**. Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients. *ESC Heart Fail*. 2022 Jun;9(3):1666-1676. doi: 10.1002/ehf2.13879. Epub 2022 Apr 1. PMID: 35362255
5. Cuomo A, Mercurio V, Pugliese M, ..., **Tocchetti CG (corresponding author)**, Passariello A. Cardiovascular events and treatment of children with high risk medulloblastoma. *EClinicalMedicine*. 2021 Dec 31;43:101251. doi: 10.1016/j.eclinm.2021.101251. eCollection 2022 Jan. PMID: 35024594
6. Zito C, ..., **Tocchetti CG**. Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC). *Eur Heart J Cardiovasc Imaging*. 2021 Mar 22;22(4):406-415. doi: 10.1093/ehjci/jeaa339. PMID: 33432333.
Highlighted in the Editorial: Jutta Bergler-Klein. Myocardial damage in anthracyclines and breast cancer: take a look at the bull's eye. *Eur Heart J Cardiovasc Imaging*. 2021 Mar 22;22(4):416-417. doi: 10.1093/ehjci/jeab020.
7. Bosso G, Mercurio V, ..., **Tocchetti CG (co-last author)**, Schiraldi F. Time-weighted lactate as a predictor of adverse outcome in acute heart failure. *ESC Heart Fail*. 2021 Feb;8(1):539-545. doi: 10.1002/ehf2.13112. PMID: 33231918
8. **Tocchetti CG (corresponding author)**, Ameri P, et al. Novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. *Cardiovasc Res*. 2020 Sep 1;116(11):1820-1834. doi: 10.1093/cvr/cvaa222. PMID: 32683451
9. Mercurio V, Cuomo A, ..., **Tocchetti CG**. What is the cardiac impact of chemotherapy and subsequent radiotherapy in lymphoma patients? *Antioxid Redox Signal*. 2019 Nov 20;31(15):1166-1174. doi: 10.1089/ars.2019.7842
10. Russo M, Guida F, ..., **Tocchetti CG**. [The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity](#). *Eur J Heart Fail*. 2019 Apr;21(4):519-528. doi: 10.1002/ejhf.1439

Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society

150 words maximum

- 2022-2024 Chair of the Basic Science Section and Executive Board Member of the HFA
- 2020-2022 Chair of the WG of Myocardial Function and Chair of the HFA Study Group of Cardio-Oncology and Chair of the HFA Committee on Basic & Translational Research, organizer of several workshops.
- Coordinator of the HFA Winter Research Meeting since 2023
- Author of many HFA and ESC scientific and position papers and statements, including the 2022 ESC guidelines on Cardio-Oncology (Author) and the 2021 ESC guidelines on Heart Failure (Reviewer)

--

Why are you motivated to join the HFA Board or Nominating Committee? <i>150 words maximum</i>

Dear Giuseppe, Dear Members of the HFA Extraordinary Nominating Committee 2023-2024, It has been an immense pleasure and honour to work with you in the Executive Board of the HFA. We have conducted exciting projects and scientific and position papers, and developed insightful congresses such as the HFA Main congress and the Winter meeting that I am coordinating since 2023 (we are already organizing the Winter Meeting in 2025!) and other workshops and smaller meetings. I would be delighted to continue working on these tasks with you and the rest of the HFA Board as an Ordinary Board member, as it is a privilege to share our experiences and contribute to the growth of the Heart Failure Science and patient care. Teamwork and friendship are keys to a successful and continuous collaboration. I hope you can keep my application in the highest consideration. Thank you, see you soon! Gabriele
--

How will you combine your HFA position with your daily clinical/research workload? <i>80 words maximum</i>
--

I see heart failure patients in my daily practice, and clinical and translational heart failure are my main fields of research. I am currently Chair of the Basic Science Section and Executive Board Member of the HFA, and together with the rest of the Board I am not experiencing problems in conducting exciting projects and papers, and developing insightful congresses, such as the HFA Main congress and the Winter meeting that I am coordinating since 2023
